Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Movers and Shakers

- PMLiVE

Bioclusters benefit from pharma shake-up

Sweeping job cuts at Europe’s largest drugmakers in recent years have spread gloom through the pharma sector, but the release of talent is helping to drive the development of bioclusters

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

UK flag

UK government ‘must push for clinical trial transparency’

MP committee calls for publication of results from clinical trials using NHS treatments

- PMLiVE

UK to improve commercial viability of antibiotic research

Government unveils new research incentives as part of antimicrobial resistance strategy

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

UK market access: The importance of a local value story

Meeting the needs of the health service’s new stakeholders

- PMLiVE

Pfizer faces NICE rejection for lung cancer drug

Xalkori not cost-effective use of NHS resources in England and Wales

- PMLiVE

ViiV gets US nod for HIV drug dolutegravir

GSK and Pfizer joint venture on course for first drug launch

UK flag

UK sets aside £124m for health research projects

National Institute for Health Research to aims to revolutionise care

- PMLiVE

Pfizer sales dip as net income surges in Q2

Lipitor performance weighs heavy on the figures

- PMLiVE

GSK and Pfizer extend vaccine access programme

Pharma companies lower price of pneumococcal vaccines for developing nations

- PMLiVE

Pfizer separates branded and generic divisions

Follows spin out of animal health and nutrition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links